Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Genotype/Phenotype Correlation of MORC2 Mutations

N/ARecruitingNCT07038239
Hospices Civils de Lyon45 enrolled

Overview

The Microrchidia CW-type zinc finger 2 (MORC2) gene encodes a protein expressed in all tissues and enriched in the brain. It is involved in Charcot-Marie-Tooth disease, with mire than 30 families presenting MORC2 mutations. Recently, MORC2 mutation have been shown to be responsible for more complex phenotypes like DIFGAN: developmental delay, impaired growth, dysmorphic facies and axonal neuropathy. Different mutations are responsible from a diverse spectrum of phenotype, from CMT to DIFGAN. MORC2 is involved, through its ATPase activity, in DNA repair, chromatin remodeling and epigenetic silencing via the Human silencing hub (HUSH) complex. Our hypothesis is that the hypo- or hyper-activation of the HUSH complex by different MORC2 mutations could be responsible for different phenotypes in patients. The aim of this study is to perform a genotype-phenotype correlation study in patients presenting MORC2 mutations.

Study Type

OBSERVATIONAL

Enrollment

45

Conditions

Charcot Marie Tooth DiseaseDIFGANDevelopmental Delay (Disorder)Impaired GrowthDysmorphic Facies and Axonal Neuropathy

Interventions

Skin biopsyDIAGNOSTIC_TEST

under the arm using a 3 mm punch, with local anaesthesia, in the investigating centres.

Blood sampleDIAGNOSTIC_TEST

3 classical 4ml tubes samples per patients, using the routine blood sampling technique, in the investigating centres. For children, blood sampling volume will be adapted to the patient's weight according to L.1121-1 of the French public health code.

Eligibility

Sex: ALLMin age: 4 Years
Medical Language ↔ Plain English
Inclusion Criteria: * Presence of a mutation in the MORC2 gene, identified during an evaluation for peripheral neuropathy or intellectual disability * Patient has undergone electromyography (EMG) or is able to undergo EMG during the inclusion visit * Affiliation with the national health insurance system * Informed consent from the patient if an adult, or from parents/legal guardians if the patient is a minor Exclusion Criteria: * Presence of another mutation responsible for peripheral neuropathy or intellectual disability * Refusal to undergo biological sample collection * Regulatory exclusion criteria: * Pregnant, postpartum, or breastfeeding women * Individuals deprived of liberty by judicial or administrative decision * Individuals not affiliated with a social security system or not benefiting from an equivalent health coverage scheme

Locations (12)

CHU de Besançon

Besançon, France

RECRUITING

CHRU Brest

Brest, France

RECRUITING

CHU Grenoble

Grenoble, France

RECRUITING

CH de Versailles

Le Chesnay, France

RECRUITING

Service de Génétique moléculaire, pharmacogénétique, hormologie Hôpital Bicêtre

Le Kremlin-Bicêtre, France

RECRUITING

Hospices Civils de Lyon

Lyon, France

RECRUITING

CHU Marseille

Marseille, France

RECRUITING

CHU de Nantes

Nantes, France

RECRUITING

CH Pitié Salpêtrière

Paris, France

RECRUITING

Hôpital Necker

Paris, France

RECRUITING

...and 2 more locations

Outcomes

Primary Outcomes

Epigenetic biomarker levels

Quantification of epigenetic biomarkers in patient and control-derived cells (number of reads in patients vs controls)

Time frame: At inclusion

Secondary Outcomes

RNA-seq

quantification of specific mRNA sequences in patient-derived cells (RNA copy number in patient vs control)

Time frame: At inclusion

Detection and quantification of specific nucleic acid biomarkers in patient's serum

Quantification of nucleic acid biomarkers in the patient's serum (number of reads in patients vs control)

Time frame: At inclusion

Quantification of nucleic acid biomarkers in patient's cerebrospinal fluid

Quantification of nucleic acid biomarkers in the patient's cerebrospinal fluid (CSF) (number of reads in patients vs control)

Time frame: At inclusion

Quantification of proteic biomarkers in patient's serum

Quantification of proteic biomarkers in the patient's serum (µg/mL)

Time frame: At inclusion

Quantification of proteic biomarkers in patient's cerebrospinal fluid (CSF)

Quantification of proteic biomarkers in the patient's cerebrospinal fluid (CSF)(µg/mL)

Time frame: At inclusion

Central Contacts

Shams RIBAULT, MD

CONTACT

00334 72 07 25 73shams.ribault@chu-lyon.fr
Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.